MedTrace Logo

MA of Tryptophan in Cornmeal in Healthy Adults>60y

NCT07272668 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-09

No results posted yet for this study

Summary

The world's population will reach 12 billion by this century's end. As the human population increases, the world faces the continuous challenge of optimizing a limited food supply. Protein is the key determinant of growth and bodily function. Recently, our group showed that current protein recommendations for adults and children are underestimated by 30-50%. Animal protein production is "more resource intensive than any other form of food production" and their high saturated fat content is linked to chronic diseases in developed nations. Plant protein sources are important alternatives shown to "enhance ecosystem resilience and improve human health". Maize, commonly known as corn, is a staple food in the diets of more than 300 million Africans and ranks as the third most produced food globally. Maize supplies up to 80% of daily energy in sub-Saharan and Southern Africa alone. It is one of the main protein sources in these countries for vegetarians. Already, over 900,000 Canadians adults are vegetarians and globally plant protein consumption is encouraged. However, maize protein is limiting in the essential amino acid (EAA) tryptophan and anti-nutritional factors can affect tryptophan bioavailability (BA). Dietary protein quality (DPQ) depends on its amino acid (AA) composition and BA. Therefore, knowledge of tryptophan BA is fundamental to understand the extent to which cereal grains meet the body's requirement for protein synthesis (PS). Efforts aimed at increasing crop production and DPQ, should coincide with DPQ evaluation directly in humans so that the gap in knowledge between protein requirement and how best to provide it can be quickly and efficiently reconciled.

Conditions

  • Protein Absorption and Amino Acid Availability

Interventions

OTHER

Tryptophan

4 different tryptophan test levels 0.5, 1, 1.5 and 2 mg.kg-1.day.1

Sponsors & Collaborators

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Glenda Courtney Martin, PhD, RD · The Hospital for Sick Children

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-29
Primary Completion
2026-03-01
Completion
2026-05-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07272668 on ClinicalTrials.gov